Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
Fish and Richardson
Express Scripts
Boehringer Ingelheim

Generated: December 18, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,233,956

« Back to Dashboard

Claims for Patent: 9,233,956

Title:Benzene sulfonamide thiazole and oxazole compounds
Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
Inventor(s): Rheault; Tara Renae (Durham, NC)
Assignee: Novartis AG (Basel, CH)
Application Number:14/088,598
Patent Claims: 1. A method for treating a susceptible neoplasm selected from melanoma and non-small cell lung cancer in a mammal in need thereof comprising the steps of: (a) analyzing a sample from said neoplasm to determine whether an activating mutation is present in the coding sequence for B-Raf in cells of said neoplasm; (b) selecting a mammal having said neoplasm with an activating mutation in the coding sequence for B-Raf; and (c) administering a therapeutically effective amount the compound of formula ##STR00608## or a pharmaceutically acceptable salt thereof to the mammal selected in step (b).

2. The method of claim 1, wherein the activating mutation present in the coding sequence for BRAF results in a BRAF having an amino acid substitution selected from the group consisting of R462I, I463S, G464V, G464E, G466A, G466E, G466V, G469A, G469E, D594V, F595L, G596R, L597V, L597R, T599I, V600E, V600D, V600K, V600R, T119S, and K601E.

3. The method of claim 2, wherein the activating mutation present in the coding sequence for BRAF results in a BRAF having a V600E amino acid substitution.

4. The method of claim 1, wherein said neoplasm is melanoma.

5. The method of claim 4, wherein said neoplasm is metastatic melanoma.

6. The method of claim 1, wherein the activating mutation present in the coding sequence for BRAF results in the coding sequence of BRAF having a substitution of T1799A.

7. The method of claim 1, wherein said mammal is a human.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: